SCORE2 Report 17: Macular thickness fluctuations in anti-VEGF-treated patients with central or hemiretinal vein occlusion
Purpose To evaluate macular thickness fluctuations and their association with visual acuity outcome in eyes with macular edema (ME) secondary to central (CRVO) or hemiretinal vein occlusion (HRVO) treated initially with intravitreal aflibercept or bevacizumab. Methods Post hoc analysis of 362 patien...
Gespeichert in:
| Veröffentlicht in: | Graefe's archive for clinical and experimental ophthalmology 2022-05, Vol.260 (5), p.1491-1500 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1500 |
|---|---|
| container_issue | 5 |
| container_start_page | 1491 |
| container_title | Graefe's archive for clinical and experimental ophthalmology |
| container_volume | 260 |
| creator | Scott, Ingrid U. Oden, Neal L. VanVeldhuisen, Paul C. Ip, Michael S. Blodi, Barbara A. |
| description | Purpose
To evaluate macular thickness fluctuations and their association with visual acuity outcome in eyes with macular edema (ME) secondary to central (CRVO) or hemiretinal vein occlusion (HRVO) treated initially with intravitreal aflibercept or bevacizumab.
Methods
Post hoc analysis of 362 patients with ME secondary to CRVO or HRVO initially randomized to six monthly intravitreal injections of aflibercept or bevacizumab. Three spectral domain optical coherence tomography (SD-OCT) central subfield thickness (CST) fluctuation measures were investigated over Months 1–12: standard deviation (SD), number of turning points (T) for each participant, and a measure denoted as Zigzag reflecting the magnitude of alternating ups and downs in a participant’s CST. Main outcome measure is Month 12 visual acuity letter score (VALS).
Results
More fluctuations occurred in eyes randomized to bevacizumab than aflibercept: SD (59.98 vs 32.12;
p
|
| doi_str_mv | 10.1007/s00417-021-05494-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2604467397</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2604467397</sourcerecordid><originalsourceid>FETCH-LOGICAL-c419t-204622e306b53a0b916d770d7db847cadab6bc0472910d57349e5a74adffd01c3</originalsourceid><addsrcrecordid>eNp9kc1uEzEUhS0EoqHwAiyQJTZsDNd_4ww7FKUFqahSC6g7y2PfIS6TmWB7QH37OqSA1EVXvtb5zrF1DyEvObzlAOZdBlDcMBCcgVatYvoRWXAlNTMgrh6TBZgqLaW4OiLPcr6GykvNn5IjqZZKtEu1IDeXq_OLtaAXuJtSody8p5-dnweXaNlE_2PEnGk_zL7MrsRpzDSO1I0lsm_r0xNWErqCge6qiGPJ9HcsG-rrmNxAp0Q3uI0JSxzr9RdW7-T9MOea9Jw86d2Q8cXdeUy-nqy_rD6ys_PTT6sPZ8wr3hYmQDVCoISm09JB1_ImGAPBhG6pjHfBdU3nQRnRcgjaSNWidka50PcBuJfH5M0hd5emnzPmYrcxexwGN-I0ZysaUKoxsjUVfX0PvZ7mVL--p1Tdl9awp8SB8mnKOWFvdyluXbqxHOy-GHsoxtZi7J9irK6mV3fRc7fF8M_yt4kKyAOQqzR-x_T_7QdibwFFuJi8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2649845507</pqid></control><display><type>article</type><title>SCORE2 Report 17: Macular thickness fluctuations in anti-VEGF-treated patients with central or hemiretinal vein occlusion</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Scott, Ingrid U. ; Oden, Neal L. ; VanVeldhuisen, Paul C. ; Ip, Michael S. ; Blodi, Barbara A.</creator><creatorcontrib>Scott, Ingrid U. ; Oden, Neal L. ; VanVeldhuisen, Paul C. ; Ip, Michael S. ; Blodi, Barbara A. ; SCORE2 Investigator Group ; for the SCORE2 Investigator Group</creatorcontrib><description>Purpose
To evaluate macular thickness fluctuations and their association with visual acuity outcome in eyes with macular edema (ME) secondary to central (CRVO) or hemiretinal vein occlusion (HRVO) treated initially with intravitreal aflibercept or bevacizumab.
Methods
Post hoc analysis of 362 patients with ME secondary to CRVO or HRVO initially randomized to six monthly intravitreal injections of aflibercept or bevacizumab. Three spectral domain optical coherence tomography (SD-OCT) central subfield thickness (CST) fluctuation measures were investigated over Months 1–12: standard deviation (SD), number of turning points (T) for each participant, and a measure denoted as Zigzag reflecting the magnitude of alternating ups and downs in a participant’s CST. Main outcome measure is Month 12 visual acuity letter score (VALS).
Results
More fluctuations occurred in eyes randomized to bevacizumab than aflibercept: SD (59.98 vs 32.12;
p
< 0.0001), T (4.03 vs 3.53;
p
= 0.02) and Zigzag (24.91 vs 11.60;
p
= 0.0003). Month 12 VALS is significantly lower for the 4th (highest) quartile of the CST fluctuation measure than for the 1st (lowest) quartile for both SD (mean difference in VALS of 7.87; 95% confidence interval: 3.03, 12.70) and Zigzag (mean difference in VALS of 5.11; 95% confidence interval: 0.29, 9.93). SD and Zigzag quartiles were no longer significantly different after Month 1 VALS was added to the regression analysis.
Conclusions
Greater CST fluctuation as assessed by SD and Zigzag was negatively associated with Month 12 VALS. However, early post-treatment VALS is a stronger predictor of VALS outcomes than the CST fluctuation measures.</description><identifier>ISSN: 0721-832X</identifier><identifier>EISSN: 1435-702X</identifier><identifier>DOI: 10.1007/s00417-021-05494-5</identifier><identifier>PMID: 34842984</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Acuity ; Angiogenesis Inhibitors ; Bevacizumab ; Confidence intervals ; Edema ; Humans ; Intravitreal Injections ; Macular Edema - diagnosis ; Macular Edema - drug therapy ; Macular Edema - etiology ; Medicine ; Medicine & Public Health ; Occlusion ; Ophthalmology ; Patients ; Retinal Disorders ; Retinal Vein Occlusion - complications ; Retinal Vein Occlusion - diagnosis ; Retinal Vein Occlusion - drug therapy ; Tomography, Optical Coherence ; Treatment Outcome ; Valsartan - therapeutic use ; Vascular endothelial growth factor ; Vascular Endothelial Growth Factors</subject><ispartof>Graefe's archive for clinical and experimental ophthalmology, 2022-05, Vol.260 (5), p.1491-1500</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021</rights><rights>2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</rights><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c419t-204622e306b53a0b916d770d7db847cadab6bc0472910d57349e5a74adffd01c3</citedby><cites>FETCH-LOGICAL-c419t-204622e306b53a0b916d770d7db847cadab6bc0472910d57349e5a74adffd01c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00417-021-05494-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00417-021-05494-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34842984$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Scott, Ingrid U.</creatorcontrib><creatorcontrib>Oden, Neal L.</creatorcontrib><creatorcontrib>VanVeldhuisen, Paul C.</creatorcontrib><creatorcontrib>Ip, Michael S.</creatorcontrib><creatorcontrib>Blodi, Barbara A.</creatorcontrib><creatorcontrib>SCORE2 Investigator Group</creatorcontrib><creatorcontrib>for the SCORE2 Investigator Group</creatorcontrib><title>SCORE2 Report 17: Macular thickness fluctuations in anti-VEGF-treated patients with central or hemiretinal vein occlusion</title><title>Graefe's archive for clinical and experimental ophthalmology</title><addtitle>Graefes Arch Clin Exp Ophthalmol</addtitle><addtitle>Graefes Arch Clin Exp Ophthalmol</addtitle><description>Purpose
To evaluate macular thickness fluctuations and their association with visual acuity outcome in eyes with macular edema (ME) secondary to central (CRVO) or hemiretinal vein occlusion (HRVO) treated initially with intravitreal aflibercept or bevacizumab.
Methods
Post hoc analysis of 362 patients with ME secondary to CRVO or HRVO initially randomized to six monthly intravitreal injections of aflibercept or bevacizumab. Three spectral domain optical coherence tomography (SD-OCT) central subfield thickness (CST) fluctuation measures were investigated over Months 1–12: standard deviation (SD), number of turning points (T) for each participant, and a measure denoted as Zigzag reflecting the magnitude of alternating ups and downs in a participant’s CST. Main outcome measure is Month 12 visual acuity letter score (VALS).
Results
More fluctuations occurred in eyes randomized to bevacizumab than aflibercept: SD (59.98 vs 32.12;
p
< 0.0001), T (4.03 vs 3.53;
p
= 0.02) and Zigzag (24.91 vs 11.60;
p
= 0.0003). Month 12 VALS is significantly lower for the 4th (highest) quartile of the CST fluctuation measure than for the 1st (lowest) quartile for both SD (mean difference in VALS of 7.87; 95% confidence interval: 3.03, 12.70) and Zigzag (mean difference in VALS of 5.11; 95% confidence interval: 0.29, 9.93). SD and Zigzag quartiles were no longer significantly different after Month 1 VALS was added to the regression analysis.
Conclusions
Greater CST fluctuation as assessed by SD and Zigzag was negatively associated with Month 12 VALS. However, early post-treatment VALS is a stronger predictor of VALS outcomes than the CST fluctuation measures.</description><subject>Acuity</subject><subject>Angiogenesis Inhibitors</subject><subject>Bevacizumab</subject><subject>Confidence intervals</subject><subject>Edema</subject><subject>Humans</subject><subject>Intravitreal Injections</subject><subject>Macular Edema - diagnosis</subject><subject>Macular Edema - drug therapy</subject><subject>Macular Edema - etiology</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Occlusion</subject><subject>Ophthalmology</subject><subject>Patients</subject><subject>Retinal Disorders</subject><subject>Retinal Vein Occlusion - complications</subject><subject>Retinal Vein Occlusion - diagnosis</subject><subject>Retinal Vein Occlusion - drug therapy</subject><subject>Tomography, Optical Coherence</subject><subject>Treatment Outcome</subject><subject>Valsartan - therapeutic use</subject><subject>Vascular endothelial growth factor</subject><subject>Vascular Endothelial Growth Factors</subject><issn>0721-832X</issn><issn>1435-702X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kc1uEzEUhS0EoqHwAiyQJTZsDNd_4ww7FKUFqahSC6g7y2PfIS6TmWB7QH37OqSA1EVXvtb5zrF1DyEvObzlAOZdBlDcMBCcgVatYvoRWXAlNTMgrh6TBZgqLaW4OiLPcr6GykvNn5IjqZZKtEu1IDeXq_OLtaAXuJtSody8p5-dnweXaNlE_2PEnGk_zL7MrsRpzDSO1I0lsm_r0xNWErqCge6qiGPJ9HcsG-rrmNxAp0Q3uI0JSxzr9RdW7-T9MOea9Jw86d2Q8cXdeUy-nqy_rD6ys_PTT6sPZ8wr3hYmQDVCoISm09JB1_ImGAPBhG6pjHfBdU3nQRnRcgjaSNWidka50PcBuJfH5M0hd5emnzPmYrcxexwGN-I0ZysaUKoxsjUVfX0PvZ7mVL--p1Tdl9awp8SB8mnKOWFvdyluXbqxHOy-GHsoxtZi7J9irK6mV3fRc7fF8M_yt4kKyAOQqzR-x_T_7QdibwFFuJi8</recordid><startdate>20220501</startdate><enddate>20220501</enddate><creator>Scott, Ingrid U.</creator><creator>Oden, Neal L.</creator><creator>VanVeldhuisen, Paul C.</creator><creator>Ip, Michael S.</creator><creator>Blodi, Barbara A.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20220501</creationdate><title>SCORE2 Report 17: Macular thickness fluctuations in anti-VEGF-treated patients with central or hemiretinal vein occlusion</title><author>Scott, Ingrid U. ; Oden, Neal L. ; VanVeldhuisen, Paul C. ; Ip, Michael S. ; Blodi, Barbara A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c419t-204622e306b53a0b916d770d7db847cadab6bc0472910d57349e5a74adffd01c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Acuity</topic><topic>Angiogenesis Inhibitors</topic><topic>Bevacizumab</topic><topic>Confidence intervals</topic><topic>Edema</topic><topic>Humans</topic><topic>Intravitreal Injections</topic><topic>Macular Edema - diagnosis</topic><topic>Macular Edema - drug therapy</topic><topic>Macular Edema - etiology</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Occlusion</topic><topic>Ophthalmology</topic><topic>Patients</topic><topic>Retinal Disorders</topic><topic>Retinal Vein Occlusion - complications</topic><topic>Retinal Vein Occlusion - diagnosis</topic><topic>Retinal Vein Occlusion - drug therapy</topic><topic>Tomography, Optical Coherence</topic><topic>Treatment Outcome</topic><topic>Valsartan - therapeutic use</topic><topic>Vascular endothelial growth factor</topic><topic>Vascular Endothelial Growth Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Scott, Ingrid U.</creatorcontrib><creatorcontrib>Oden, Neal L.</creatorcontrib><creatorcontrib>VanVeldhuisen, Paul C.</creatorcontrib><creatorcontrib>Ip, Michael S.</creatorcontrib><creatorcontrib>Blodi, Barbara A.</creatorcontrib><creatorcontrib>SCORE2 Investigator Group</creatorcontrib><creatorcontrib>for the SCORE2 Investigator Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Graefe's archive for clinical and experimental ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Scott, Ingrid U.</au><au>Oden, Neal L.</au><au>VanVeldhuisen, Paul C.</au><au>Ip, Michael S.</au><au>Blodi, Barbara A.</au><aucorp>SCORE2 Investigator Group</aucorp><aucorp>for the SCORE2 Investigator Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>SCORE2 Report 17: Macular thickness fluctuations in anti-VEGF-treated patients with central or hemiretinal vein occlusion</atitle><jtitle>Graefe's archive for clinical and experimental ophthalmology</jtitle><stitle>Graefes Arch Clin Exp Ophthalmol</stitle><addtitle>Graefes Arch Clin Exp Ophthalmol</addtitle><date>2022-05-01</date><risdate>2022</risdate><volume>260</volume><issue>5</issue><spage>1491</spage><epage>1500</epage><pages>1491-1500</pages><issn>0721-832X</issn><eissn>1435-702X</eissn><abstract>Purpose
To evaluate macular thickness fluctuations and their association with visual acuity outcome in eyes with macular edema (ME) secondary to central (CRVO) or hemiretinal vein occlusion (HRVO) treated initially with intravitreal aflibercept or bevacizumab.
Methods
Post hoc analysis of 362 patients with ME secondary to CRVO or HRVO initially randomized to six monthly intravitreal injections of aflibercept or bevacizumab. Three spectral domain optical coherence tomography (SD-OCT) central subfield thickness (CST) fluctuation measures were investigated over Months 1–12: standard deviation (SD), number of turning points (T) for each participant, and a measure denoted as Zigzag reflecting the magnitude of alternating ups and downs in a participant’s CST. Main outcome measure is Month 12 visual acuity letter score (VALS).
Results
More fluctuations occurred in eyes randomized to bevacizumab than aflibercept: SD (59.98 vs 32.12;
p
< 0.0001), T (4.03 vs 3.53;
p
= 0.02) and Zigzag (24.91 vs 11.60;
p
= 0.0003). Month 12 VALS is significantly lower for the 4th (highest) quartile of the CST fluctuation measure than for the 1st (lowest) quartile for both SD (mean difference in VALS of 7.87; 95% confidence interval: 3.03, 12.70) and Zigzag (mean difference in VALS of 5.11; 95% confidence interval: 0.29, 9.93). SD and Zigzag quartiles were no longer significantly different after Month 1 VALS was added to the regression analysis.
Conclusions
Greater CST fluctuation as assessed by SD and Zigzag was negatively associated with Month 12 VALS. However, early post-treatment VALS is a stronger predictor of VALS outcomes than the CST fluctuation measures.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>34842984</pmid><doi>10.1007/s00417-021-05494-5</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0721-832X |
| ispartof | Graefe's archive for clinical and experimental ophthalmology, 2022-05, Vol.260 (5), p.1491-1500 |
| issn | 0721-832X 1435-702X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2604467397 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Acuity Angiogenesis Inhibitors Bevacizumab Confidence intervals Edema Humans Intravitreal Injections Macular Edema - diagnosis Macular Edema - drug therapy Macular Edema - etiology Medicine Medicine & Public Health Occlusion Ophthalmology Patients Retinal Disorders Retinal Vein Occlusion - complications Retinal Vein Occlusion - diagnosis Retinal Vein Occlusion - drug therapy Tomography, Optical Coherence Treatment Outcome Valsartan - therapeutic use Vascular endothelial growth factor Vascular Endothelial Growth Factors |
| title | SCORE2 Report 17: Macular thickness fluctuations in anti-VEGF-treated patients with central or hemiretinal vein occlusion |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T11%3A13%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=SCORE2%20Report%2017:%20Macular%20thickness%20fluctuations%20in%20anti-VEGF-treated%20patients%20with%20central%20or%20hemiretinal%20vein%20occlusion&rft.jtitle=Graefe's%20archive%20for%20clinical%20and%20experimental%20ophthalmology&rft.au=Scott,%20Ingrid%20U.&rft.aucorp=SCORE2%20Investigator%20Group&rft.date=2022-05-01&rft.volume=260&rft.issue=5&rft.spage=1491&rft.epage=1500&rft.pages=1491-1500&rft.issn=0721-832X&rft.eissn=1435-702X&rft_id=info:doi/10.1007/s00417-021-05494-5&rft_dat=%3Cproquest_cross%3E2604467397%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2649845507&rft_id=info:pmid/34842984&rfr_iscdi=true |